Inhibitors of glycogen synthase kinase 3

US7425557B2 · kind B2 · utility

Assignee

• Novartis Vaccines and Diagnostics, Inc. · US

Inventors

• John M. Nuss · Danville, US
• Stephen Harrison · Benicia, US
• David B. Ring · Palo Alto, US
• Rustum Boyce · San Francisco, US
• Kirk W. Johnson · Berkeley, US
• Keith B. Pfister · Emeryville, US
• Savithri Ramurthy · Walnut Creek, US
• Lynn Seely · San Mateo, US
• Allan S. Wagman · Belmont, US
• Manoj C. Desai · Pleasant Hill, US
• Barry Haskell Levine · Lafayette, US

Key dates

• Filing date: Sep 6, 2005
• Grant date: Sep 16, 2008
• Expiry date: Oct 7, 2026

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D417/14
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

New pyridine-based compounds of Formula I, compositions, and methods of inhibiting the activity of glycogen synthase kinase (GSK3) in vitro and of treatment of GSK3-mediated disorders in vivo are provided. The methods, compounds, and compositions of the invention may be employed alone, or in combination with other pharmacologically active agents in the treatment of disorders mediated by GSK3 activity, such as diabetes, Alzheimer's disease and other neurodegenerative disorders, obesity, atherosclerotic cardiovascular disease, essential hypertension, polycystic ovary syndrome, syndrome X, ischemia, traumatic brain injury, bipolar disorder, immunodeficiency or cancer.